PIERIS PHARMACEUTICALS INC's ticker is PIRS and the CUSIP is 720795103. A total of 96 filers reported holding PIERIS PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $4,708 | +284.3% | 25,700 | +281.9% | 0.00% | – |
| Q4 2023 | $1,225 | -38.9% | 6,730 | 0.0% | 0.00% | – |
| Q3 2023 | $2,006 | +80.1% | 6,730 | 0.0% | 0.00% | – |
| Q2 2023 | $1,114 | -93.6% | 6,730 | -62.0% | 0.00% | – |
| Q1 2023 | $17,304 | +30.7% | 17,730 | +39.3% | 0.00% | – |
| Q4 2022 | $13,239 | -87.7% | 12,730 | -64.4% | 0.00% | – |
| Q1 2022 | $108,000 | -33.7% | 35,776 | -17.0% | 0.00% | – |
| Q4 2021 | $163,000 | -55.0% | 43,120 | -38.4% | 0.00% | – |
| Q3 2021 | $362,000 | +36100.0% | 70,055 | +23251.7% | 0.00% | – |
| Q1 2021 | $1,000 | – | 300 | +435.7% | 0.00% | – |
| Q2 2020 | $0 | -100.0% | 56 | -91.5% | 0.00% | – |
| Q1 2020 | $2,000 | 0.0% | 656 | +9.3% | 0.00% | – |
| Q4 2019 | $2,000 | -89.5% | 600 | -89.1% | 0.00% | – |
| Q3 2019 | $19,000 | +375.0% | 5,500 | +587.5% | 0.00% | – |
| Q2 2019 | $4,000 | – | 800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 1,360,000 | $6,895,000 | 5.06% |
| Omega Fund Management, LLC | 778,230 | $3,946,000 | 2.91% |
| BVF INC/IL | 5,346,838 | $27,108,000 | 2.65% |
| Virtus ETF Advisers LLC | 152,550 | $773,000 | 0.68% |
| SPHERA FUNDS MANAGEMENT LTD. | 842,632 | $4,272,000 | 0.59% |
| Tekla Capital Management LLC | 2,087,380 | $10,583,000 | 0.40% |
| Schonfeld Strategic Advisors LLC | 828,600 | $4,201,000 | 0.23% |
| Orbimed Advisors | 3,140,000 | $15,920,000 | 0.19% |
| Lombard Odier Asset Management (USA) Corp | 563,878 | $2,859,000 | 0.19% |
| Rhenman & Partners Asset Management AB | 300,000 | $1,521,000 | 0.16% |